The GQIcombi cocktail attenuates glioblastoma growth in vivo using the rat glioblastoma 101/8 model.

Abstract

Glioblastoma remains an incurable malignancy, driving the continuous search for novel therapeutic strategies. A significant challenge in this pursuit is the transition from in vitro models to in vivo efficacy. Building on our previously patented GQIcombi strategy (Patent RU2820200C2), this study investigates its efficacy in vivo using the rat 101/8 glioblastoma model. We evaluated various administration regimens of the GQIcombi cocktail, which was previously effective against patient-derived human glioma cell cultures. Although we attempted to reduce the dosing frequency to optimize the protocol, our results confirm that sequential exposure to the GQIcombi components is necessary to effectively inhibit tumor growth in vivo, mirroring its requirement in cell cultures.